6. Mayzent

Novartis headquarters
(Novartis)

Active ingredient: siponimod
Disease: secondary progressive multiple sclerosis
Peak sales estimate: $1.3 billion
Approved: March 26, 2019
Company: Novartis

The scoop: Mayzent may be just one of many multiple sclerosis drugs approved in recent years, but it has a distinguishing feature: It’s cleared in the secondary progressive form of the disease, and it was the first to win that distinction in more than 15 years when the FDA approved it back in March. That go-ahead gave Novartis a shot at a big market, as 80% of patients with relapsing remitting MS go on to develop SPMS. The thing is, it’s not always easy for patients—or their doctors—to tell when that’s happened. So far, uptake has been slow; in the third quarter, Mayzent generated just $4 million in sales, less than half of the $10 million analysts expected it to see. Novartis CEO Vas Narasimhan, M.D., blamed a 90-day sales lag that arose out of reimbursement issues. — Carly Helfand

6. Mayzent

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.